Schedule 13G ownership disclosure

Zentalis Pharmaceuticals, Inc.

Common Stock, $0.001 par value per share · CUSIP: 98943L107

Event date: 2025-01-29

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Walters William T

    Shares: 7,050,000.00 · Class: 9.9%

  • WALTERS GROUP

    Shares: 7,050,000.00 · Class: 9.9%

  • Walters, Susan B.

    Shares: 7,050,000.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002053359-25-000002
Form type
SCHEDULE 13G/A
Filer
Walters William T
CIK
CIK 1689655
Filed
Jan 31, 2025
Reporting period
Jan 29, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub